Popular on TelAve
- NWIDA Welcomes Matt Zieminski to Board of Directors as Legislative Strategy Lead
- Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- Philadelphia HVAC Company Bypasses Paid Search Ads, Citing Cost Savings for Customers
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- Legendary N.W.A. CoFounder & Tech Visionary OG Arabian Prince Joins Tech Coast Venture Network Board
- TNT Removal & Disposal Celebrates Record Year Helping Pennsylvania Property Owners Reclaim Space
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- Former Irvine Mayor Farrah Khan Joins Tech Coast Venture Network Board
- Qualis LLC Appoints Jeremy Mallicoat as Chief Financial Officer to Advance Growth and Acquisition Strategy
Similar on TelAve
- 30th Anniversary of the Netscape IPO, Behind the Scenes of the Web's Spectacular Success
- Jones Sports Announces Enhanced Leadership
- Bay Miner Goes Global with Mobile Mining App for Everyday BTC, ETH & XRP Earnings
- Databahn Reveals Smart Sales Agent for Strategic Account Plans
- Boingo Emerges as the #1 Platform for Finding Real Estate in Mexico — Outpacing Traditional Portals
- Timeline of Events that Made the Spectacular Netscape IPO Possible
- NASA Agreement for Applications in PV Power Beaming; $5 Million to $20 Million Sales Projection for 2026 and $25 Million to $40 Million for 2027 $ASTI
- Juego Studios Rises as Global Leader in Full-Cycle Game Development, Design, & Outsourcing
- The Secret to Consistent Sales? It's Not More Leads—It's a Repeatable System
- SolMining announces $88 million in funding
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference
TelAve News/10871709
Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer
SAN JOSE, Calif., Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, virtually and in-person at the Briar Club in Houston, Texas.
Dr. Wenham will join leading experts in the field to discuss advancements in ovarian cancer research and therapies, including Anixa's CAR-T therapy. The presentation is scheduled for Thursday, September 18, 2025, from 12:05 PM – 12:30 PM CT.
Ovarcome is an ovarian cancer foundation envisioned to end the scourge of ovarian cancer. The Ovarcoming Cancer Conference brings together survivors, caregivers, and medical professionals to learn from world renowned experts on topics of greatest importance in the ovarian cancer landscape.
For more information about the conference, visit Ovarcoming Cancer Annual Conference 2025 - Ovarcome.
More on TelAve News
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
More on TelAve News
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
[email protected]
408-708-9808
SOURCE Anixa Biosciences, Inc.
SAN JOSE, Calif., Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, virtually and in-person at the Briar Club in Houston, Texas.
Dr. Wenham will join leading experts in the field to discuss advancements in ovarian cancer research and therapies, including Anixa's CAR-T therapy. The presentation is scheduled for Thursday, September 18, 2025, from 12:05 PM – 12:30 PM CT.
Ovarcome is an ovarian cancer foundation envisioned to end the scourge of ovarian cancer. The Ovarcoming Cancer Conference brings together survivors, caregivers, and medical professionals to learn from world renowned experts on topics of greatest importance in the ovarian cancer landscape.
For more information about the conference, visit Ovarcoming Cancer Annual Conference 2025 - Ovarcome.
More on TelAve News
- Bay Miner Goes Global with Mobile Mining App for Everyday BTC, ETH & XRP Earnings
- Databahn Reveals Smart Sales Agent for Strategic Account Plans
- Editorial Freelancers Association and Thurgood Marshall College Fund Announce Partnership to Advance Editorial Careers for HBCU Students
- ASI Showcasing Constituent Engagement Solutions at ASAE Annual Meeting & Spotlighting iMIS® Partner Marketplace
- LIB's Walk-In Environmental Chambers: Scalable, Specialized, and Built for Industry Extremes
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
More on TelAve News
- Vitanergy Health US Inc. Launches Three New Women's Supplements in the US: Vegan, Clean-Label, and Made in the USA
- Fibrecross Unveils Multi-Core Fiber Coupling Connectors
- Boingo Emerges as the #1 Platform for Finding Real Estate in Mexico — Outpacing Traditional Portals
- Karapancev Law Welcomes New Associate Lawyers as Firm Expands Capacity
- eJoule Supplies Wyon Swiss Batteries High Performance Single Crystal Cathode Active Material
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
[email protected]
408-708-9808
SOURCE Anixa Biosciences, Inc.
Filed Under: Business
0 Comments
Latest on TelAve News
- Top Dentist In Denver, Sloan's Lake Dental, Surpasses 600 5-Star Reviews While Redefining Compassionate Care
- The 17th annual Hola México Film Festival, presented by Toyota, will feature the opening night screening of the film "Autos, Mota y Rocanrol."
- The Secret to Consistent Sales? It's Not More Leads—It's a Repeatable System
- HAR Dental Integrates X-Guide Technology for Precision Implant Surgery
- BitTitan Appoints Florent Aonon to Lead EMEA Sales Amid Continued Global Growth
- The GENIUS Act Kicks Off a New Era of Compliance — WinnerMining Helps XRP & ETH Holders Passively Grow Their Assets
- ABC Quant Launches Risk Shell AI Platform (Beta II Release Candidate)
- CCHR: Psychiatric Commitment of the Homeless is a Dangerous, Costly Failure
- Quality Homes & Luxury Lifestyle at Heritage at South Brunswick!
- New Frontier Aerospace and Air Force Institute of Technology Sign CRADA to Advance Hypersonic VTOL Aircraft
- Say Goodbye to Summer! Easing the Mental Health Transition Back to School
- $750 Million Projected Market; NRx Pharmaceuticals, Inc files Citizens Petition to FDA Seeking Removal of Benzethonium Chloride from Ketamine Products
- TUHLULA DA VIRGO – The Rise of a Star
- SolMining announces $88 million in funding
- Top Edu-Tainment IP, Badanamu, enters children's mental health space, launching Healthy Kids Music Network
- Costa Oil Partners with Rick Ware Racing for NASCAR Cup Series Debut at Iowa Speedway
- DARA Abrams NYC Stories Art Experience at One Art Space
- Buildout Unveils Rethink+: Revolutionizing Commercial Real Estate Prospecting with Seamless CRM Integration
- purelyIV Launches Niagen® IV Therapy – A Breakthrough in NAD+ Cellular Wellness
- Jewellok Unveils Cutting-Edge Specialty Gas Changeover Manifolds to Revolutionize Industrial and Medical Gas Delivery